All News

The Bladder Cancer Advocacy Network provides insight into the ongoing cisplatin shortage.

“Our results support the notion that mpMRI is an inadequate screening tool for locally advanced [prostate cancer] and should not be used as the sole means of presurgical [prostate cancer] staging," wrote the authors.

The AI model was accurate and effective in an independent test set, according to the study authors.

The findings of harassment and inappropriate behavior come at a time when there is widespread agreement among health care leaders about the need for a more diverse physician workforce.

PFD Week is an inclusive meeting that offers access to internationally recognized leaders in the field and the opportunity to network with the most respected professionals in Urogynecology.

The multiplex polymerase chain reaction/pooled antibiotic susceptibility test was associated with a 44.4% lower mean total UTI-related cost compared to standard urine culture.

"Clinicians have opportunities to reduce patient subjective and objective financial burden if they continue to self-educate and communicate with patients and consider [financial toxicitiy] an adverse effect of treatment," write Alexandria A. Spellman, MD, MS, and Deborah R. Kaye, MD, MS.

Flotufolastat F 18 was granted FDA approval on May 25, 2023 based on data from the phase 3 SPOTLIGHT and LIGHTHOUSE trials.

"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.

Among patients who did not have a response during the first cycle, 60.8% achieved a response after the fourth.

Automating prior authorization is an investment that every health care organization should consider. As the industry grapples with rapid regulatory shifts and acute staff shortages, a tailored automation strategy is key to enhancing patient care and improving operational efficiency.

The approval is based on findings from the phase 3 TALAPRO-2 trial.

5-year OS was similar between the cohorts, with a rate of 57% among patients who underwent RARC, compared with 55% among those who underwent ORC.

The theranostic 64Cu/67Cu-SAR-BBN combines the imaging product 64Cu-SAR-BBN and the targeted therapy 67Cu-SAR-BBN.

The investigators assessed data from the UNITE study, a retrospective study of patients treated with enfortumab vedotin and other agents.

“Our results suggest that bladder-sparing treatments may be a safe approach in selected patients. Survival outcomes were not inferior compared to early radical cystectomy," says Wei Shen Tan, MD.

Pelvic lymph node involvement and polymetastases detected with PSMA-PET imaging were linked to significantly lower overall survival rates in patients initially diagnosed with non-metastatic, castration-resistant prostate based on conventional imaging.

Treatment with the first-line combination of pembrolizumab and lenvatinib led to durable anti-tumor activity in patients with non–clear cell renal cell carcinoma.

Clinical research has demonstrated a 10-minute onset interval for the topical gel formulation MED3000, compared to an interval of at least 30 minutes with PDE5 inhibitors, such as Cialis and Viagra.

"The most alarming finding is that there were 0 instances of DREs in the NAMCS dataset over the entire 5-year period, and there were no PSAs conducted in American Indian/Alaska Native men after 2014,” says Christopher M. Gillette, PhD.

"This [guideline]... is probably the most broad in scope and incorporates a lot of the things that were missing or not yet mature enough to be included in the previous guidelines," says Badrinath Konety, MD, MBA.

"TAR-200 is a sort of a pretzel device. It's a novel drug delivery mechanism that's placed inside the bladder for sustained release of gemcitabine," explains Siamak Daneshmand, MD.

"We successfully demonstrated that the overexpression of TRAF4 prompts the conversion of androgen-sensitive prostate cancer cells into castration-resistant cells,” says Ping Yi, PhD.

"The addition of an immune checkpoint inhibitor after tri- or tetra-modality therapy might improve long-term outcomes for patients with bladder cancer,” said Maria De Santis, MD.

A total of 74.3% of respondents indicated that more training dedicated to care for patients in the LGBT community was needed.

Telehealth is here to stay. Lean into the technology as the new line of business that it is.

“Combined MRI-targeted and systematic biopsies were nearly twice as likely to result in downgraded pathology at prostatectomy compared [with] systematic biopsies," says Ilon C. Weinstein.

The economic burden is based on three components: excess medical care expenditures, lost labor market productivity, and premature death.